Active, not recruitingPhase 1NCT06175338

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

Studying NON RARE IN EUROPE: Rheumatoid arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mabscale, LLC
Intervention
Rituximab(drug)
Enrollment
208 target
Eligibility
18-65 years · All sexes
Timeline
20232025

Study locations (12)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06175338 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Rheumatoid arthritis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Rheumatoid arthritis

← Back to all trials